

Percent survival
100
80
60
40
20
0
0
10
20
30
Days after randomization
Saline
17G8.72
27A12.70
29E7.35
42H11.51

FIG. 1



EF (%)
50
40
30
20
10
0
Saline
17G8.72
27A12.70
29E7.35
42H11.51
Groups

FIG. 2



Percent survival
100
80
60
40
20
0
0
10
20
30
Days after randomization
Saline
33E3.10

FIG. 3



EF (%)
30
20
10
0
Saline
33E3.10
Groups

FIG. 4



FIG. 5A



FIG. 5B



EDV
175
150
125
100
75
50
EDV (ul)
0
1
2
3
4
Weeks after MI
*
#
Saline
Isotype
Anti-EDA

FIG. 5C



ESV
150
125
100
75
50
25
0
ESV (uL)
0
1
2
3
4
Weeks after MI
*
#
*
Saline
Isotype
Anti-EDA

FIG. 5D



Neutrophils
*
Ly6G+ neutrophils ( x10^6 cells/ml)
0.8
0.6
0.4
0.2
0.0
Control
Anti-EDA

FIG. 6A



T-cells
CD3+ T-cells (x10^6 cells/ml)
2.0
1.5
1.0
0.5
0.0
Control
Anti-EDA

FIG. 6B



Ly6C+ monocytes
Ly6C+Ly6G- monocytes (X10^6 cells/ml)
0.08
0.06
0.04
0.02
0.00
Control
Anti-EDA

FIG. 6C



Ly6C- monocytes
Ly6C- Ly6G- monocytes (x10^6 cells/ml)
0.05
0.04
0.03
0.02
0.01
0.00
Control
Anti-EDA

FIG. 6D



*
CD49d on Ly6C- monocytes
(median intensity)
5
4
3
2
1
0
Saline
Anti-EDA

FIG. 6E



IL-1β
GM-CSF
TNF-α
MIP-1β
RANTES
IL-10
IL-17
IL-4
pg/mL
Control
Anti-EDA

FIG. 7A




FIG. 7B





FIG. 7C




FIG. 7D





FIG. 7E




FIG. 8A





FIG. 8B



Col1 mRNA
Corrected relative expression
1.5
1.0
0.5
0.0
Control
Anti-EDA

FIG. 8C



Col3 mRNA
Corrected relative expression
1.5
1.0
0.5
0.0
Control
Anti-EDA

FIG. 8D





FIG. 9A FIG. 9B





FIG. 9C



Vessels in border
p<0.0001
p=0.09
vessels/mm2
0
20
40
60
80
5-10 µm
10-16 µm
16-24 µm
> 24 µm
Classes
Control
Anti-EDA

FIG. 9D



Total vessels infarct
p=0.05
vessels/mm2
0
20
40
60
80
100
Control
Anti-EDA
Treatment
Control
Anti-EDA

FIG. 9E





FIG. 9F




FIG. 9G




FIG. 9H





FIG. 9I

Control




FIG. 10A

Anti-EDA




FIG. 10B





FIG. 10C



MMP2
inactive
intermediate
Active
Control
Infarct
Remote
Anti-EDA
Infarct
Remote
Control
Infarct
Remote
Anti-EDA
Infarct
Remote
Control
Infarct
Remote

FIG. 10D





FIG. 10E





FIG. 10F





FIG. 10G





FIG. 10H



Infarcted area H&E
Infarcted area EDA
Border of infarct EDA
1-5 days
1-2 weeks
>1 month
A
B
C
D
E
F
G
H
I

FIG. 11





FIG. 12A





FIG. 12B